AstraZeneca (NYSE:AZN) fell about 5% on Thursday, having plunged as much as 9% earlier in the day, after its closely watched Phase III CARDIO-TTRansform trial failed. At its worst, the setback wiped roughly £19 billion (about US$24 billion) off the company's value, though the shares clawed back some of that loss through the session. For…